U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07244367) titled 'Maintenance Venetoclax in AML Fit Patients' on Nov. 17.
Brief Summary: this study will explore the efficacy of maintenance SC cytarabine + venetoclax therapy as regard disease free survival (DFS) in AML fit patients who achieved CR after highly aggressive chemotherapy as bridge for BMT or if BMT will be delayed or canceled due to any other reason.
Study Start Date: Sept. 01
Study Type: INTERVENTIONAL
Condition:
Acute Myeloid Leukaemia (AML)
Intervention:
DRUG: SC cytarabine +Venetoclax
SC Cytarabine (20 mg) administrated on days 1-7 ,,Venetoclax (100 mg ) administrated on days 1-7,,Voriconazole 200 mg 1x2 administrated on day...